Filing Flows › Comparisons › TGTX vs SUPN
TG Therapeutics vs Supernus Pharmaceuticals: TGTX and SUPN compared
TG Therapeutics is the larger company: $240M of revenue in its latest quarter (Q2 2026) against $227M for Supernus Pharmaceuticals (Q3 2026). TG Therapeutics is growing faster (+70% against +18% a year earlier). Supernus Pharmaceuticals is more profitable, with an operating margin of 9.3% against 9.0%.
Where the money goes: TGTX and SUPN
TG Therapeutics (TGTX) · Q2 2026
TG Therapeutics, Q2 2026: revenue $240M (+70% year over year), operating margin 9.0%, net earnings $7.8M, operating cash flow $39.3M. The chart follows the revenue to costs, profit and cash.
Supernus Pharmaceuticals (SUPN) · Q3 2026
Supernus Pharmaceuticals, Q3 2026: revenue $227M (+18% year over year), operating margin 9.3%, net earnings $20.9M, operating cash flow $6.6M. The chart follows the revenue to costs, profit and cash.
| TG Therapeutics (TGTX) | Supernus Pharmaceuticals (SUPN) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $240M | $227M |
| Revenue growth, Y/Y | +70% | +18% |
| Operating margin | 9.0% | 9.3% |
| Net earnings | $7.8M | $20.9M |
| Net margin | 3.2% | 9.2% |
| Operating cash flow | $39.3M | $6.6M |
| Free cash flow | $39.0M | $6.4M |
| Market value | $8.7B | — |
| P/E | 19.7× | — |
| Analysts’ mean target | $69.71 | — |
Where the revenue comes from
TG Therapeutics
- Product: $236M (98%)
- License: $4.5M (2%)
Supernus Pharmaceuticals
- Net product sales: $179M (79%)
- ONAPGO: $17.1M (8%)
- Trokendi XR: $10.2M (5%)
- Oxtellar XR: $8.0M (4%)
Questions
Which is bigger, TG Therapeutics or Supernus Pharmaceuticals?
TG Therapeutics is the larger company: $240M of revenue in its latest quarter (Q2 2026) against $227M for Supernus Pharmaceuticals (Q3 2026).
Is TG Therapeutics or Supernus Pharmaceuticals growing faster?
TG Therapeutics is growing faster (+70% against +18% a year earlier).
Which is more profitable, TG Therapeutics or Supernus Pharmaceuticals?
Supernus Pharmaceuticals is more profitable, with an operating margin of 9.3% against 9.0%.
More: TG Therapeutics earnings · how TG Therapeutics makes money · Supernus Pharmaceuticals earnings · how Supernus Pharmaceuticals makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 5, 2026; 10-Q filed Oct 29, 2026). Fiscal quarters can end on different dates. Not investment advice.